A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma

Patients will receive a 2-hour intravenous infusion of study drug (LY573636) once every 21
days or 28 days depending on their target dose. Radiological imaging scans will be performed
before the first dose of study drug and then after every other treatment. Patients will be
assessed for clinical progression at every visit and for response approximately every 42 days
or 56 days (every other cycle).

Inclusion Criteria:

- Diagnosis of soft tissue sarcoma that is unresectable or metastatic

- Have received one or two (but no more than two) prior treatment regimens for
metastatic soft tissue sarcoma, one of which must have included doxorubicin
(adriamycin).

- Must have stopped all previous treatments for cancer, including chemotherapy,
radiation therapy or other investigational treatments for cancer for at least 30 days

Exclusion Criteria:

- Participants with primary bone sarcoma (for example osteosarcoma, Ewing's sarcoma,
chondrosarcoma), gastrointestinal stromal tumor (GIST) and Kaposi's sarcoma

- Serious pre-existing medical problems (as determined by your doctor)

- Have received more than two previous systemic treatment regimens for unresectable or
metastatic soft tissue sarcoma

- Have a second primary cancer (unless cancer-free for more than 2 years)

- Active treatment with Warfarin (Coumadin)